MwanzoNVAX • NASDAQ
add
Novavax Inc
$ 8.10
Baada ya Saa za Kazi:(0.49%)+0.040
$ 8.14
Imefungwa: 17 Okt, 19:50:08 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 8.48
Bei za siku
$ 8.02 - $ 8.36
Bei za mwaka
$ 5.01 - $ 11.50
Thamani ya kampuni katika soko
1.32B USD
Wastani wa hisa zilizouzwa
4.60M
Uwiano wa bei na mapato
3.54
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 239.24M | -42.42% |
Matumizi ya uendeshaji wa biashara | 53.28M | -53.23% |
Mapato halisi | 106.51M | -34.41% |
Kiwango cha faida halisi | 44.52 | 13.92% |
Mapato kwa kila hisa | 0.62 | -37.37% |
EBITDA | 113.23M | -34.63% |
Asilimia ya kodi ya mapato | 0.88% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 612.30M | -41.66% |
Jumla ya mali | 1.34B | -26.51% |
Jumla ya dhima | 1.30B | -42.28% |
Jumla ya hisa | 37.62M | — |
hisa zilizosalia | 162.42M | — |
Uwiano wa bei na thamani | 36.87 | — |
Faida inayotokana na mali | 20.09% | — |
Faida inayotokana mtaji | 126.06% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 106.51M | -34.41% |
Pesa kutokana na shughuli | -127.46M | -140.56% |
Pesa kutokana na uwekezaji | 111.10M | 129.81% |
Pesa kutokana na ufadhili | -1.04M | -100.40% |
Mabadiliko halisi ya pesa taslimu | -9.50M | -104.76% |
Mtiririko huru wa pesa | -124.92M | -122.15% |
Kuhusu
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company's first and only commercial product is the Novavax COVID-19 vaccine. The company is also developing vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax also develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1987
Makao Makuu
Tovuti
Wafanyakazi
952
